目的:了解评价血浆置换(PE)治疗慢性乙型重型肝炎的临床疗效及价值。方法:观察重型肝炎患者PE前后总胆红素、白蛋白5项指标及乏力、腹胀等临床症状变化,比较治疗组和对照组治疗后好转率的差异。统计分析PE治疗及次数与患者预后的关系。检测部分患者PE前后内毒素(LPS)浓度,探讨LPS与患者预后的关系。结果:治疗组和对照组早中期患者好转率分别为54.4％和27.8％(Plt;0.01);晚期患者的好转率分别为8.3％和1.4％(Pgt;0.05)。PE治疗2到4次,患者的好转率分别为39.4％、43.6％和42.9％,但PE次数在不同组别患者的好转率之间差异无统计学意义(Pgt;0.05)。PE治疗后好转患者血清内毒素浓度下降(Plt;0.01)。结论:PE能明显改善患者肝功能指标,提高早中期患者的好转率。PE次数为2到4次时,患者的好转率较高,但不同的PE次数未显示相应患者的临床转归之间有统计学意义的差异。血清LPS浓度与患者预后有相关性,治疗前血清LPS浓度低且治疗后下降者,预后较好;相反,治疗前血清LPS浓度高且治疗后下降不明显者,预后较差。
Serum marker Golgi protein 73 (GP73) is a type Ⅱ integral membrane protein located in cellular Golgi apparatus. GP73 not only processes proteins, but also participates in cell differentiation, intercellular signaling, and apoptosis. With the development of proteomics technology, GP73 has been used as a novel serum marker for detecting liver diseases. This article reviews the research progress of GP73 in the clinical diagnosis value and prognosis prediction of chronic hepatitis B in recent years, in order to provide new ideas for the diagnosis and treatment of patients with chronic hepatitis B.
At present, the most commonly used nucleoside (acid) anaog (NAs) treatment regimen in clinical practice cannot completely cure chronic viral hepatitis B (CHB). However, although the polyethylene glycol interferon treatment regimen is superior to the NAs regimen in terms of immune mechanism, it has the disadvantage of low hepatitis B virus DNA response rate. In recent years, the cure of CHB is being studied all over the world. Various mechanisms and drug targets are being explored, and diversified therapeutic strategies are also being used. Clinical cure of hepatitis B is possible, but it is still in the early stage, and many potential drugs and better therapeutic strategies are still being tested. This article mainly reviews the latest progress in the treatment of CHB based on the recent research achievements in direct antiviral drugs and host immunotherapy as well as the research progress in combination therapy.
目的 探讨替比夫定治疗乙肝e抗原（HBeAg）阳性慢性乙型肝炎（CHB）患者72周的疗效及预测因素的分析。 方法 选择2007年9月－2012年9月符合入选标准的82例CHB患者接受替比夫定治疗72周，于治疗前基线、治疗后每3个月查丙氨酸氨基转移酶（ALT）、乙肝病毒DNA（HBV DNA）、乙肝病毒血清标志物，观察治疗期间累计生化学应答率、完全病毒学应答率(CVR)、HBeAg血清学转换率（SR）及耐药率，分析基线ALT水平[分为＜5 ULN（正常值检测下限）组及≥5 ULN组]、HBV DNA水平（分为＜107 copies/mL组及≥107 copies/mL组）、24周HBV DNA水平（＜3 log 10 copies/mL组及≥3 log 10 copies/mL组），预测72周CVR及SR。 结果 172周累计生化学应答率、CVR、SR、耐药率分别为86.6%、81.7%、42.7%、18.2%；2基线ALT≥5 ULN对72周SR有预测价值（χ2=5.651，P=0.017），HBV DNA＜107 copies/mL对CVR有预测价值（χ2=7.083，P=0.008）；324周HBV DNA＜103 copies/mL对72周CVR及SR均有预测价值（χ2=27.339，5.131；P=0.000，0.023）。 结论 替比夫定初治HBeAg阳性CHB患者疗效及安全性好，治疗24周HBV DNA＜103 copies/mL是72周疗效的最佳预测指标。
Objective To analyze the clinical characteristics of individuals with high hepatitis B virus (HBV) pregenomic RNA (pgRNA), and further explore the value of pgRNA in the management of patients with chronic hepatitis B. Methods From December 1st, 2020 to April 1st, 2022, chronic hepatitis B patients who had been treated with nucleotide analogues for a long time and followed up in the Hepatitis Clinic of the Center of Infectious Diseases, West China Hospital, Sichuan University were included, and the clinical characteristics of chronic hepatitis B patients with high pgRNA were analyzed and summarized. Results A total of 107 patients were included. Male patients accounted for 66.4%, with an average age of 44.02 years. There were no statistically significant differences in gender, age, aspartate transaminase, alanine transaminase, γ-glutamyl transferase, HBV surface antigen, proportion of patients with HBV e antigen ≥0.1 U/mL, HBV DNA, and alpha fetoprotein between the high and low pgRNA groups (P>0.05). The proportion of patients with HBV surface antigen<100 U/mL in the high pgRNA group was lower than that in the low pgRNA group (4.4% vs. 22.6%, P<0.05). Conclusion The proportion of chronic hepatitis B patients with high pgRNA whose HBV surface antigen≥100 U/mL is higher.
ObjectiveTo evaluate the effect of autoantibody on the efficacy and safety of pegylated interferonα-2a (Peg-IFNα-2a) and ribavirin on chronic hepatitis C (HCV). MethodsWe enrolled 106 chronic HCV infected patients, who were divided into autoantibody-positive group and negative group based on the baseline autoantibody detection. The patients were treated for 48 weeks. The anti-viral response and adverse effects were observed. Data analyses were reported using the SPSS 20.0 statistical package. ResultsThe prevalence of any autoantibody in chronic hepatitis C patients amounted to 31.1%, and serum anti-nuclear antibody was positive in 24 patients. Difference in age, sex, serum alanine transaminase level, aspartate transaminase level, total bilirubin level, thyroid function and HCV RNA level between autoantibody-positive group and negative group was not significant (P > 0.05). The level of hemoglobin in autoantibody-positive group was significantly lower than the negative group (P=0.018). Of the 106 patients, 82 patients achieved sustained virological response (SVR), 56 achieved rapid virological response (RVR), 98 achieved ealy virological response (EVR) and 8 were non-responders. There were no significant differences between RVR, EVR and SVR in autoantibody-positive group and negative group (P > 0.05). The most common adverse effects in this study were fatigue, weight loss, hair loss and fever, and no significant differences in adverse effects were observed between the two groups (P > 0.05). ConclusionAutoantibody positivity may not affect the treatment response and is safe in chronic HCV infected patients with combination therapy of pegylated interferonα-2a plus ribavirin.